Review





Similar Products

rat coralite plus 488 anti mouse lamp1 antibody  (Coralite Dental Products)
86
Coralite Dental Products rat coralite plus 488 anti mouse lamp1 antibody
BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: <t>LAMP1;</t> green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.
Rat Coralite Plus 488 Anti Mouse Lamp1 Antibody, supplied by Coralite Dental Products, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamp1/488+anti+coralite+lamp1+mouse+plus+rat/pmc13191106-394-46-47
Average 86 stars, based on 1 article reviews
rat coralite plus 488 anti mouse lamp1 antibody - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
rabbit anti lamp1  (ABclonal Biotechnology)
96
ABclonal Biotechnology rabbit anti lamp1
BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: <t>LAMP1;</t> green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.
Rabbit Anti Lamp1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamp1/LAMP1+Rabbit+pAb/pm42678995-466-66-68
Average 96 stars, based on 1 article reviews
rabbit anti lamp1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti lamp1  (ABclonal Biotechnology)
96
ABclonal Biotechnology anti lamp1
BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: <t>LAMP1;</t> green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.
Anti Lamp1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamp1/LAMP1+Rabbit+pAb/pm42715837-166-11-14
Average 96 stars, based on 1 article reviews
anti lamp1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
lysosome associated membrane protein 1  (ABclonal Biotechnology)
96
ABclonal Biotechnology lysosome associated membrane protein 1
BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: <t>LAMP1;</t> green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.
Lysosome Associated Membrane Protein 1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamp1/LAMP1+Rabbit+pAb/pmc13604869-86-45-52
Average 96 stars, based on 1 article reviews
lysosome associated membrane protein 1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
abflo 594 anti lamp1  (ABclonal Biotechnology)
96
ABclonal Biotechnology abflo 594 anti lamp1
BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: <t>LAMP1;</t> green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.
Abflo 594 Anti Lamp1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamp1/LAMP1+Rabbit+pAb/pm42674255-121-36-39
Average 96 stars, based on 1 article reviews
abflo 594 anti lamp1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti lamp1 antibody  (ABclonal Biotechnology)
96
ABclonal Biotechnology anti lamp1 antibody
BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: <t>LAMP1;</t> green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.
Anti Lamp1 Antibody, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamp1/LAMP1+Rabbit+pAb/pm42551360-60-8-10
Average 96 stars, based on 1 article reviews
anti lamp1 antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
lamp1  (ABclonal Biotechnology)
96
ABclonal Biotechnology lamp1
BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: <t>LAMP1;</t> green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.
Lamp1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamp1/LAMP1+Rabbit+pAb/pm42480904-147-32-31
Average 96 stars, based on 1 article reviews
lamp1 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: LAMP1; green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.

Journal: Bioactive Materials

Article Title: Countering postoperative immune suppression with a self-assembling dendritic cell nanovaccine

doi: 10.1016/j.bioactmat.2026.05.005

Figure Lengend Snippet: BAITs promote DC activation and antigen presentation via enhanced lysosomal processing. (A) Schematic for MHC Ⅰ/Ⅱ immunostaining. DCs were treated with antigens or BAITs (12 h), then incubated in fresh medium (with TGFβ) for 24 h before staining. (B, C) Quantification of surface MHC Ⅰ (B) and MHC Ⅱ (C) on DCs (n = 8; n.s. is P > 0.05, ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by one-way ANOVA with Bonferroni post-hoc test). (D, E) Representative immunofluorescence images of DCs (blue: nuclei; yellow: LAMP1; green: MHC Ⅰ; magenta: MHC Ⅱ). BAIT-treated DCs show strong surface MHC and minimal intracellular antigen signal, whereas antigen-treated DCs show retained antigen (red) and weak surface MHC signal. (F–H) Flow cytometric analysis of MHC Ⅰ (F), MHC Ⅱ (G), and CD80 (H) expression on murine CD11c + DCs after exposure to antigens or BAITs. (I) Quantification of MHC Ⅰ, MHC Ⅱ, and CD80 expression in DCs by flow cytometry (n = 3; ∗∗∗ is P < 0.001, ∗∗∗∗ is P < 0.0001 by two-way ANOVA with Bonferroni post-hoc test). (J) Heatmap of DC activation-related gene expression after treatment with antigens or BAITs, highlighting upregulation of maturation and antigen presentation genes and downregulation of immunosuppressive genes by BAITs (n = 3). Data are presented as mean ± SD.

Article Snippet: After treatment, the cells were washed twice with PBS and fixed in 4% paraformaldehyde for 20 min. For intracellular protein staining, fixed cells were permeabilized with 0.1% Triton X-100 at room temperature for 10 min. Next, the cells were blocked with 2% BSA and incubated with rat CoraLite Plus 488 anti-mouse LAMP1 antibody (1:200) and rabbit anti-mouse pSAP (1:200) antibody overnight at 4 °C.

Techniques: Activation Assay, Immunopeptidomics, Immunostaining, Incubation, Staining, Immunofluorescence, Expressing, Flow Cytometry, Gene Expression